National Procurement for HIV and Preventative Treatments
key details
| Value | £270,000,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 7 Sept 2021 |
| Contract start | 1 Feb 2022 |
| Contract end | 31 Jul 2023 |
| Procedure | open |
| SME suitable | No |
| OCID | ocds-b5fd17-679c8a51-8d80-4a5a-a099-01eb80b9f1b8 |
Awards (15)
This procurement was awarded to 15 suppliers. Values shown are per-award; the notice total is £270,000,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Abbvie Ltd shared | £230,000,000 | 1 Feb 2022 | active |
| Amarox Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Dr.Reddy's Laboratories (UK) Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Gilead Sciences Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Glenmark Pharmaceuticals Europe Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Janssen-Cilag Ltd shared | £230,000,000 | 1 Feb 2022 | active |
| Lupin Healthcare (UK) Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Macleods Pharma UK Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Mawdsley-Brooks & Co Ltd shared | £230,000,000 | 1 Feb 2022 | active |
| Merck Sharpe & Dohme (UK) Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Mylan shared | £230,000,000 | 1 Feb 2022 | active |
| Teva UK Limited shared | £230,000,000 | 1 Feb 2022 | active |
| Tillomed Laboratories ltd shared | £230,000,000 | 1 Feb 2022 | active |
| ViiV Healthcare shared | £230,000,000 | 1 Feb 2022 | active |
| Zentiva Pharma UK Ltd shared | £230,000,000 | 1 Feb 2022 | active |
description
Lot 1 - supply of licensed antiretroviral therapy (ART) for the treatment of HIV (Adults and Children) and licensed pre-exposure prophylaxis (PrEP) packs for the prevention of HIV.
Lot 2 - a service to supply over labelled post-exposure prophylaxis (PEP) packs for the prevention of HIV.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 8 Mar 2022 | Award (award) | · | 7e53ca94-3652-4574-97be-28251c036a94-516643 |
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.